NA-AION Risk Factors: New Perspectives

CompletedOBSERVATIONAL
Enrollment

179

Participants

Timeline

Start Date

August 1, 2021

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2024

Conditions
Non-arteritic Ischemic Optic NeuropathyOptic Disk Drusen
Trial Locations (20)

80309

University og Colorado, Boulder

84132

John A. Moran Eye Center, Salt Lake City

94143

UCSF Medical Center, San Francisco

94305

Stanford Medicine, Palo Alto

02114

Massachusetts Eye and Ear, Boston

Unknown

Sydney Eye Hospital, Sydney

University of Calgary, Calgary

Research St. Joseph's, Hamilton

Lawson Health Research Institute, London

Aalborg University Hospital, Aalborg

Aarhus University Hospital, Aarhus

Odense University Hospital, Odense

Zealand University Hospital, Roskilde

Bordeaux University Hospital, Bordeaux

Farabi Eye Hospital, Tehran

Sheba Medical Center, Tel Aviv

Capital and Coast DHB, Wellington

University of Cambridge, Cambridge

King's College Hospital, London

Moorfield's Eye Hospital, London

All Listed Sponsors
collaborator

Velux Fonden

OTHER

collaborator

Fight for Sight

OTHER

collaborator

University of Copenhagen

OTHER

collaborator

Hamilton Health Sciences Corporation

OTHER

collaborator

Aarhus University Hospital

OTHER

collaborator

Aalborg University Hospital

OTHER

collaborator

Odense University Hospital

OTHER

collaborator

Farabi Eye Hospital

OTHER

collaborator

Wellington Hospital

OTHER_GOV

collaborator

University of Colorado, Denver

OTHER

collaborator

University of Utah

OTHER

collaborator

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

collaborator

University of Sydney

OTHER

collaborator

Stanford University

OTHER

collaborator

Moorfields Eye Hospital NHS Foundation Trust

OTHER

collaborator

Massachusetts Eye and Ear Infirmary

OTHER

collaborator

University Hospital, Bordeaux

OTHER

collaborator

Synoptik-Fonden

UNKNOWN

lead

Rigshospitalet, Denmark

OTHER

NCT05305079 - NA-AION Risk Factors: New Perspectives | Biotech Hunter | Biotech Hunter